FROM THE EXPO FLOOR- Rashmi Kumari of Neo Science Hub walks through analytica Lab India & PharmaCore India 2026. She spent three days navigating all three pavilions — Pavilion 1 (laboratory instruments and technology), Pavilion 2 (pharma value chain, finished formulations, CDMO, and digital solutions), and Pavilion 3 (specialised analytical equipment and laboratory infrastructure) — speaking with exhibitors, observing demonstrations, and taking notes on what the product mix collectively revealed about the priorities of India’s pharma and laboratory science industry in 2026.
There is a particular quality of organised intensity that distinguishes a well-curated trade fair from a mere product exhibition. analytica Lab India and PharmaCore India 2026, spread across three pavilions of the Jio World Convention Centre in Bandra Kurla Complex, had that quality from the first morning. The floor was alive — not with the performative bustle of brand activation events, but with the purposeful movement of people who had come to buy, compare, evaluate, and decide. Scientists walked slowly past instrument booths, pausing to ask technical questions. Procurement managers sat across tables with brochures spread between them. Startup founders lingered at booths of global instrument majors, doing mental arithmetic about what their laboratory could afford and when.
PAVILION 1: THE INSTRUMENTS FLOOR — PRECISION, AUTOMATION, AND THE RACE TO MINIATURISE
The gold-themed Pavilion 1 housed the instruments exhibitors, and it set the analytical technology tone for the entire fair.
Analytik Jena India Pvt. Ltd. — Booth E032 arrived with two products that occupied opposite ends of the analytical challenge spectrum. The first, the PULSEspencer R, addresses a surprisingly underappreciated bottleneck in high-throughput laboratory work: the time and variability introduced by manual pipetting, dilution series preparation, and sample normalisation. The instrument eliminates all three steps, enabling what the company described as “true miniaturisation” — faster setup, lower reagent consumption, and reproducible results without the human-error component that plagues manual assay preparation. The second product, the multi N/C 4300 TOC analyser, targets pharmaceutical ultrapure water quality — a critical compliance requirement — using UV digestion without the persulfate reagent that conventional TOC analysers require. The ability to analyse highly acidic or alkaline matrices without persulfate, using flow injection technology, makes it particularly suited to the aggressive-chemistry environments common in formulation and API quality control labs.
At Cole-Parmer — Booth A005, the demonstration of the Single-Use Dispensing Pump powered by i-FILL drew sustained interest from visitors working in biologics fill-finish operations. The hybrid piston-diaphragm architecture is the key engineering claim: it delivers the volumetric accuracy of a piston pump while using the fluid-isolation principle of a diaphragm pump, making it uniquely appropriate for shear-sensitive, high-value biological formulations. Single-use fluid path assemblies eliminate cleaning validation requirements and cross-contamination risk entirely — a meaningful operational advantage for contract manufacturers handling multiple biologics molecules in sequence.
eDiscovery Automation Pvt. Ltd. — Booth C053 showcased robotic powder dispensing systems from XQ Instruments, Singapore, covering the range from 2 mg to 8 g with stated accuracy of ±3% and a cycle time of two to three seconds per dose. For laboratories running high-throughput compound screening or early-stage formulation work, the replacement of manual powder dispensing — tedious, slow, and prone to consistency failures — with automated precision dispensing represents a genuine productivity multiplier.
Artlab India — Booth D005 presented the Vayu Fumehood, an eco-friendly laboratory fume containment system certified to SEFA and ASHRAE standards. The product’s key differentiator is its high containment performance at low face velocities — a combination that reduces energy consumption without compromising laboratory safety. Anti-corrosion construction and a redesigned form factor round out what the company positioned as a next-generation laboratory safety solution for the Indian market.
Kesar Control Systems Private Limited — Booth A001 occupied what might seem like an unglamorous niche — stability chambers — but in the pharmaceutical context, there is nothing unglamorous about a product that directly determines whether a drug’s shelf-life claims stand up to regulatory scrutiny. Kesar’s chamber replicates the four ICH stability zones through controlled temperature and relative humidity cycling, giving pharmaceutical manufacturers the environmental data their stability dossiers require.
Labtop Instruments Private Limited — Booth E033 made a compelling case for waterless humidity technology in stability testing. The LABTOP Waterless Stability Chamber eliminates the water reservoir that conventional chambers require, removing with it the risks of mineral scaling, biological contamination, and the maintenance burden of regular reservoir cleaning. The company positioned this as particularly valuable for accelerated stability studies — where extended continuous operation makes reservoir-related maintenance failures a genuine regulatory and operational risk.
LabGuard India Pvt. Ltd. — Booth E001 drew steady traffic to its Yoga Series Table, a modular, plug-and-play laboratory workstation that addresses a problem every laboratory manager recognises but few trade fairs ever address: the inflexibility of fixed laboratory furniture in the face of constantly evolving workflows, equipment, and protocols. Crank-based height adjustment between 750 and 900 mm, integrated power and gas access, modular storage, and compatibility with HPLC setups make this a genuinely reconfigurable workstation rather than merely a table with drawers. The product spoke directly to the reality that Indian laboratories — particularly growing CROs and biotech startups — cannot afford to renovate their physical infrastructure every time their analytical setup changes.
I R Technology Services Pvt. Ltd. — Booth C043 showcased a portfolio of elemental and materials analysis instruments covering carbon, sulphur, oxygen, nitrogen, and hydrogen analysers, XRF analysers, microwave digestion systems, industrial microscopes, and handheld XRF units. The product range serves both R&D and industrial quality control, and the booth attracted visitors from API manufacturing operations where elemental impurity analysis has become a regulatory obligation following ICH Q3D.
YK Analytical Corporation — Booth C055 presented the Freezing Point Osmometer — a niche but important instrument for pharmaceutical and bioscience quality control. Osmolality measurement of water-based solutions is critical in ophthalmology, injectable formulation development, and cell culture media preparation, and the freezing-point depression method is the pharmacopoeial reference technique for this determination.
PAVILION 2: THE PHARMA VALUE CHAIN — FROM API TO EXPORT MARKET
If Pavilion 1 was the instruments floor, Pavilion 2 was the business floor — and it was the larger, louder, and more diverse of the two pharma-facing spaces. Finished formulation manufacturers, CDMO operators, API producers, excipient suppliers, merchant exporters, packaging innovators, regulatory services providers, and digital platform companies had all staked their territory here.
ACG Associated Capsules Pvt. Ltd. — Booth F001 anchored the pavilion’s opening row with a bold proposition: a single partner capable of covering the entire oral solid dosage manufacturing process, from granulation and tablet compression through encapsulation, coating, blister packaging, and intelligent inspection. ACG’s claim of holistic OSD coverage — including high-potency API containment and end-to-end track and trace — is not merely a marketing convenience. It addresses a genuine pain point: the accountability complexity that arises when multiple vendors are responsible for different stages of a manufacturing process. Fewer suppliers means cleaner responsibility lines when something goes wrong.
Stallion Laboratories Pvt. Ltd. — Booth H021 was one of the most product-diverse booths in Pavilion 2, presenting four distinct products that together illustrated the breadth of a mid-sized Indian pharmaceutical manufacturer’s portfolio. Entrestal (Sacubitril + Valsartan 200 mg) is a guideline-aligned heart failure therapy whose manufacture requires precise fixed-dose combination formulation and stringent bioequivalence performance — a complex product that signals manufacturing maturity. Fosfostal (Fosfomycin 3g Sachet) addresses uncomplicated UTIs through a single-dose regimen that radically simplifies treatment compliance. Lecetam MR 1000 (Levetiracetam Modified Release) addresses the epilepsy management problem of dosing frequency through sustained-release technology. And MYMIN Syrup — a clinically balanced essential amino acid and vitamin supplement — serves the nutritional rehabilitation market. The range, spanning cardiovascular, anti-infective, neurological, and nutritional therapeutic categories, reflects the kind of portfolio diversification that makes a company resilient to individual molecule patent cliff risk.
At the same booth, Exceload Women’s Formula — a premium nutraceutical blend of multivitamins, minerals, antioxidants, and natural extracts targeting women’s health — signalled Stallion’s move into the nutraceutical adjacency, one of the fastest-growing commercial spaces in Indian healthcare.
Montage Laboratories Pvt. Ltd. — Booth G021 brought three hormonal contraceptive and gynaecological products to the expo floor: Medroxyprogesterone Acetate Injection (a long-acting injectable progestin for contraception and gynaecological management), Levonorgestrel + Ethinyloestradiol Tablets (combined oral contraceptive), and Norethisterone Enanthate + Estradiol Valerate Injection (combined long-acting injectable contraceptive). The fourth product, Dydrogesterone Tablets, targets progesterone deficiency conditions including luteal phase defect, threatened miscarriage, and endometriosis. The Montage portfolio is a specialist one — focused on women’s reproductive health — and its presence at PharmaCore India reflects the growing global demand for affordable hormonal therapy in emerging markets, where Indian manufacturers hold a structural cost advantage.
Encube Ethicals — Booth G001 showcased its topical product portfolio including Cetaphil, Diclofenac Sodium Gel, Docosanol Cream, and Canestan — well-established dermatological and topical pain management formulations. Encube’s strength lies in its ability to manufacture complex topical formulations to US and European standards, a capability set that serves both domestic branded market and regulated export channels.
Indoco Remedies Limited — Booth F005 presented a service-heavy proposition under three banners: Indoco Analytical Solutions (analytical contract services), Anacipher CRO (clinical research and pharmacovigilance services), and Indoco Analytical Solution Stability Testing. The analytical service portfolio covers Nitrosamine impurity testing, Elemental Impurity testing, extractables and leachables (E&L), thermal analysis, and polymorphism characterisation — a menu that tracks precisely with the emerging regulatory priorities of CDSCO, FDA, and EMA. The stability testing offering covers all four ICH climate zones, providing the global geographic coverage that exporters require for multi-regional submissions.
INGA Pharmaceuticals — Booth I023 has been in the business since 1974 — a longevity that itself speaks to execution quality. The company’s specialty positioning in anti-migraine, anti-gout, gynaecology, and dermatology, combined with its contract manufacturing partnerships with multinational corporations, makes it an example of the niche-but-global model that India’s mid-tier pharma sector has quietly perfected.
Fourrts (India) Laboratories Pvt. Limited — Booth F021 presented a broad finished formulation range spanning coated and uncoated tablets, capsules, liquid orals, creams, ointments, and medicated toothpaste. The simplicity of the company’s value proposition — quality and affordable products for patients — belies a manufacturing complexity that covers multiple dosage forms across therapeutic categories.
Halewood Laboratories Pvt. Ltd. — Booth F027 presented its Electrorush ORD Ready-to-Drink ORS product alongside its broader Electrorush range in powder, effervescent powder, and effervescent tablet formats. With a production capacity of approximately 15 million ORS pouches per month and supply relationships with MNCs across the world, Halewood’s ORS claim is not promotional: oral rehydration therapy remains the most cost-effective intervention against dehydration-related child mortality globally, and a manufacturing infrastructure at this scale has genuine public health significance.
Base Medico Private Limited — Booth H015 offered one of the broadest therapeutic category lists in the exhibition — covering antidiabetics, cardiac agents, proton pump inhibitors, thrombopoietin receptor agonists, antithyroid agents, antiepileptics, antidepressants, antipsychotics, phosphate binders, nootropics, antihistamines, anticholinergics, alpha-1 adrenergic blockers, and rheumatoid drugs. The range reflects a contract manufacturing operation of substantial capability and regulatory compliance depth.
Avik Pharmaceutical Ltd. — Booth G024 brought a focused corticosteroid API portfolio to the expo: Beclomethasone Dipropionate (asthma and allergic rhinitis), Betamethasone Dipropionate (eczema, psoriasis, dermatitis), Budesonide (COPD and asthma), Clobetasol Propionate (resistant skin conditions), Prednisolone Sodium Phosphate (acute systemic inflammation), and Prednisolone Metasulfobenzoate (emergency-grade inflammatory conditions). Corticosteroid APIs are a specialised chemistry domain — the steroid nucleus requires synthetic expertise and stringent quality systems — and Avik’s focused positioning in this category represents a coherent portfolio strategy.
SG Healthcare Pvt. Ltd. — Booth F042 presented contract manufacturing and export services for ARV (antiretroviral) drugs, psychotropic agents, immunosuppressants, antidiabetics, and cardiovascular formulations — precisely the categories where small quantities of high-value specialised products are needed in export markets with different regulatory and logistical barriers. The offer of documentation support for product registration in Rest of World markets is a meaningful value-add that addresses the registration bottleneck that prevents many small exporters from capitalising on global demand.
S Kant Healthcare Ltd — Booth H001 offered a global pharmaceutical manufacturing and export service across multiple therapeutic segments, with explicit emphasis on regulatory support and consistent quality standards that enable faster market entry for international partners.
Samrudh Pharmacare Pvt. Ltd. — Booth G011 presented external dosage products including acetaminophen suppositories, bisacodyl suppositories, and clotrimazole cream — a product range that may appear modest but addresses genuine formulation capability: suppository manufacturing requires specific temperature-controlled filling and packaging infrastructure that not all CMOs possess. The sibling entity Samrudh Pharmaceuticals Pvt. Ltd. presented as a contract manufacturing organisation specialising in hospital-use injectables — anesthetics, critical care injectables, dry powder filling, liquid injectables, and veterinary injectables — supported by WHO-GMP compliance.
Synokem — Booth G015 presented as a CDMO with six state-of-the-art manufacturing units covering tablets, capsules, ointments, creams, gels, oral liquids, injectables, eye and ear drops, and sachets. The explicit availability of both Product-to-Product (P2P) and Loan License partnership models signals commercial flexibility that smaller pharma companies — which may have registrations but not manufacturing assets — will find highly relevant.
Copmed Pharmaforce Group — Booth I011 offered contract manufacturing across a broad pharmaceutical category list covering cephalosporin and beta-lactam categories, general category products, and hormones, with distribution and export capabilities covering APIs, finished dosage forms, and veterinary products.
Forever Lifescience Pvt. Ltd. — Booth G023 and Pulse Pharmaceuticals Pvt. Ltd. — Booth G035 occupied adjacent territory in the topical and nutraceutical space respectively. Forever Lifescience’s external preparation portfolio — creams, ointments, gels, shampoos, lotions — demonstrates a 1,300-kg manufacturing capacity through modern semi-solid manufacturing equipment. Pulse Pharmaceuticals brought what it described as science-driven medical and performance nutrition powder formulations — spray-dried and blended powders across clinical, general, and sports nutrition categories — with a 10,000 sq ft R&D facility, capacity for 75 tonnes per month of spray-dried and 150 tonnes of dry-blend powders, and global distribution to Africa, Asia Pacific, CIS, MENA, GCC, and LATAM. Pulse’s ability to execute end-to-end white-label nutrition solutions across those geographies attracted considerable interest from merchant exporters visiting the booth.
Asoj Soft Caps Pvt. Ltd. — Booth H037 presented softgel finished formulations from its Baroda facility, active since 1984 and approved by NAFDAC (Nigeria), FDA Ghana, MOH Cambodia, PPB Kenya, MOHAP UAE, and multiple other regulatory authorities. Softgel manufacturing is a specialised dosage form capability — requiring dedicated encapsulation equipment and the formulation expertise to manage lipid-based drug delivery — and Asoj’s multi-country regulatory approvals suggest a credible export track record.
Allied — Booth H032, with more than 20 years in pharmaceutical process machinery and equipment, showcased pharmaceutical-grade processing tanks, cleanroom furniture, tablet compression tooling storage, and change parts and spares for encapsulation and blister packing machinery. The proposition — tailor-made solutions aligned to user requirement specifications — addresses a persistent frustration of pharmaceutical manufacturers who often find that generic equipment vendors cannot accommodate their specific process and compliance constraints.
Kamal E Industries — Booth I047 presented a complete capsule section processing and packaging machinery range — from lab scale to production scale — including capsule polishing machines, tablet and capsule counting and filling machines, double cone blenders, octagonal blenders, semi-automatic capsule fillers, and automatic capsule loaders. The company’s Parel, Mumbai address places it at the heart of India’s oldest pharmaceutical manufacturing corridor.
Thermolab Healthcare Pvt. Ltd. — Booth H011 brought the Horizontal Double Door Sterilizer — a pulse vacuum sterilisation system for hospital central sterile supply departments and operating rooms, available from 250 to 4,000 litre chamber capacities and pre-programmed with five optimised sterilisation cycles. The double-door configuration physically separates the contaminated load-side from the sterile unload-side, enforcing the infection control principle that underpins safe central sterilisation practice.
CN Water Systems Pvt. Ltd — Booth H042 presented itself as a specialist in high-purity water solutions for mission-critical industrial and pharmaceutical applications — a niche whose importance is disproportionate to its public profile. Every pharmaceutical manufacturing site requires compliant purified water and water for injection systems; the quality, reliability, and operational consistency of that water infrastructure directly determines batch release performance and regulatory audit outcomes.
MSB Chemical Limited — Booth G031 made a quiet but significant claim: it produces the world’s first US-DMF grade Absolute Alcohol (Ethanol) manufactured by an Indian indigenous analytical and pharmacopoeial-grade ethanol plant, with approvals against JP, EP, BP, IP, and US-DMF standards. For Indian pharmaceutical manufacturers exporting to regulated markets, access to a domestically produced pharmacopoeial grade ethanol with US-DMF filing eliminates an import dependency that has historically constrained supply chain resilience.
Misom Labs Limited — Booth F038 presented Pharmacopoeial Grade Ethanol as a US-DMF grade Type IV excipient solvent from its Malta-based Misom Labs Malta platform — positioning itself as a gateway for Indian manufacturers seeking compliant solvent supply with EU and UK market access capabilities.
Nitika Pharmaceutical Specialities Pvt. Ltd. — Booth F057 presented two essential excipients: Tabcell (MCC — Microcrystalline Cellulose) and Tablube/Novalube (Magnesium Stearate and Sodium Stearyl Fumarate) — the two workhorses of tablet formulation, responsible respectively for tablet structural integrity and manufacturing process lubrication. The domestic availability of pharma-grade MCC and lubricant excipients with documented supply chain quality is not a trivial offering; excipient quality failures have been a recurring source of formulation compliance problems in Indian pharmaceutical history.
Gattefosse India Pvt. Ltd. — Booth F055 presented lipidic functional excipients for oral, skin, and rectal applications — targeting the dissolution and bioavailability challenges that plague poorly soluble drug molecules. The Suppocire and Ovucire hard fat suppository base portfolio, combined with solid solubilisers and atomised powder excipients for improved bioavailability of oral formulations, positions Gattefosse as the lipid formulation technology partner for innovators and generics developers working on complex drug delivery challenges.
Ecobliss — Booth F015 brought a genuinely novel packaging concept to an audience that spends most of its time thinking about active pharmaceutical ingredients rather than packaging systems. The company’s pharmaceutical wallet — a patient-centric packaging format that integrates blister strips between cold-seal cards — keeps dosage instructions, tamper evidence, and branding with the patient through the last dose. For clinical trials, physician samples, and commercial products requiring tight medication adherence monitoring, this is not a luxury feature but a patient safety and regulatory compliance tool.
On the digital and compliance side of Pavilion 2, three exhibitors represented the accelerating digitisation of pharmaceutical operations.
ValGenesis — Booth I031 presented the Smart GxP™ Platform — an AI-enabled digital platform for process design, commissioning, qualification and validation (CQV), and ongoing verification. The core problem ValGenesis addresses is structural: pharmaceutical validation and compliance processes are historically fragmented, manual, and paper-heavy, creating the twin vulnerabilities of slow regulatory approvals and poor inspection readiness. The Smart GxP platform creates a single system of record for all validation activities, connecting related workflows, improving traceability, and maintaining compliance with 21 CFR Part 11, EU Annex 11, and ALCOA+ data integrity principles.
OASIS I-TECH Pvt. Ltd. — Booth F063 presented OASISLIMS — a pharmaceutical-specific LIMS (Laboratory Information Management System) supported by DMS, QMS, and LMS modules, with lab instrument integration for end-to-end data traceability and a data integrity architecture compliant with New Schedule ‘M’ guidelines and FDA 21 CFR Part 11. For QC and QA laboratories still operating on paper-based systems, the transition to an integrated LIMS is the single highest-leverage digitisation investment available, and OASIS’s 25-year presence in the market gives it credibility that newer SaaS entrants cannot match.
Lab Iconics Technologies LLP — Pavilion 3, Booth L055 (though positioned in Pavilion 3, it served a distinctly Pavilion 2 audience of quality and compliance professionals) presented an integrated QMS and DMS designed specifically for laboratory quality control workflows. The QMS automates deviation management, CAPA tracking, and compliance monitoring; the DMS automates the full document lifecycle from creation through version control to archiving. The explicit compliance with 21 CFR Part 11 electronic signature requirements and the use of secure version control address the data integrity vulnerabilities that CDSCO and FDA inspections continue to flag in Indian pharmaceutical facilities.
Soham ERP Solutions Pvt. Ltd. — Booth G042 presented its range of pharma-specific software products including PC 360° (Paperless ERP), PharmaCloud (cloud-based ERP for pharmaceutical formulators and bulk drug manufacturers), MR Buddy (field force monitoring), MP Exim (merchant exporters), Monitor Plus (third-party and contract manufacturing management), BarGen (barcode and PCR generation per DGFT and GS1), DrugPlus (raw material traders), PdisPlus (pharmaceutical wholesale distributors), and OMS (Order Management System). The breadth of the portfolio reflects a company that has spent decades mapping the specific workflow and compliance requirements of each segment of the Indian pharmaceutical value chain.
SYNC Consulting Services LLP — Booth G044 presented InfinitySync — an AI/ML-driven SaaS platform for end-to-end supply chain execution across procurement, production, distribution, forecasting, and warehousing. The platform’s real-time demand visibility, priority-based workflow views, and actionable dashboards address the supply chain fragmentation that plagues pharmaceutical distribution in a country where distribution infrastructure spans from metro hospital chains to rural last-mile retail.
Rosalina Instrument — Booth F061 stood out as a specialised exhibitor in radiation measurement and quality assurance, presenting the FAR-65GB Ion Chamber — a 0.65cc graphite ion chamber used to measure electron and photon beams in radiotherapy and industrial applications. Its presence at PharmaCore India reflects the broad interpretation of the pharmaceutical value chain that the show’s organisers have embraced.
TM MEDIA (Titan Biotech Ltd) — Booth F037 brought one of the broadest microbiological product portfolios to the show: over 2,500 unique formulations of dehydrated culture media for pharmaceutical microbiology, clinical diagnostics, and research laboratories. In the post-COVID regulatory environment, where CDSCO and WHO-GMP requirements for microbial quality control are more strictly enforced than ever, reliable culture media availability with documented lot-to-lot consistency is not a commodity consideration but a quality-critical procurement decision.
PAVILION 3: SPECIALISED ANALYTICAL, CONTAINMENT, AND LABORATORY INFRASTRUCTURE
Pavilion 3 housed the most technically specialised exhibitors — companies whose products serve the intersection of analytical science, containment engineering, and laboratory infrastructure management.
Shimadzu India Pvt. Ltd. — Booth J015 presented the Nexis™ GC-2060 — a next-generation gas chromatograph distinguished by its Multi-Mode Injection Unit (MMI), which supports split/splitless, programmable temperature vaporisation, direct injection, large-volume injection, thermal desorption, and extraction modes in a single injection port. The redesigned FID and TCD detectors deliver what Shimadzu described as unmatched sensitivity and stability. For pharmaceutical residual solvent analysis, pesticide residue testing in herbal APIs, and petrochemical impurity profiling, the GC-2060’s combination of injection flexibility and detector performance addresses the throughput and application range limitations of earlier generation instruments.
Metrohm India Pvt. Ltd. — Booth L053 demonstrated the i-Raman NxG — a next-generation Raman spectrometer designed for rapid quality control without sample preparation. Traditional QC methods require sample preparation, generate delays, and create production bottlenecks; the NxG analyses samples through packaging materials in seconds, enabling at-line and online quality control that was previously impossible without destructive testing.
Hanna Equipments India Pvt. Ltd. — Booth J044 presented the HI932 Automatic Potentiometric Titration System — a fully customisable advanced titrator capable of acid-base, redox, precipitation, complexometric, and non-aqueous titrations with direct measurement and back titration capability. For pharmaceutical raw material testing, where titrimetric assays remain the primary method for numerous pharmacopoeial monographs, automation of this workflow directly reduces analysis time, operator dependence, and result variability.
Hitachi High-Tech India Pvt. Ltd. — Booth M031 showcased the LA8080 AminoSAAYA amino acid analyser — a compact desktop instrument using the ninhydrin method, with a 30% smaller footprint than its predecessors, ergonomic front-access design for standing operation, and a dual-liquid mixing system that eliminates the need for reagent refrigeration. For pharmaceutical amino acid analysis, food safety testing, and nutritional product quality control, the practical daily-use improvements in the LA8080 design reflect a mature understanding of laboratory ergonomics that premium instrument pricing should always include.
SYMPATEC India Pvt. Ltd. — Booth J041 presented particle size and shape analysis capabilities using laser diffraction, high-speed image analysis (QICPIC, up to 500 frames per second), dry dispersion (RODOS), ultrasonic extinction, and dynamic light scattering. The measurement range of under 1 micron to 34,000 microns spans from nanoparticle characterisation to coarse granule analysis, covering the full breadth of pharmaceutical solid dosage development from nanosuspension through to granulation. As the inventor and pioneer of dry dispersion technology, Sympatec’s credentials in this space are foundational rather than promotional.
PCI Analytics Pvt. Ltd. — Booth O031 presented the Wall Mounting Nitrogen Generator for LC-MS/MS — a compact, space-saving alternative to pressurised nitrogen cylinders that provides constant pressure and consistent gas flow for mass spectrometry instruments. For analytical laboratories running high-throughput LC-MS/MS operations, the operational advantages of on-site nitrogen generation — no cylinder refilling logistics, no pressure variation, minimal maintenance — compound meaningfully over time.
Svan Analytical Instruments Pvt. Ltd. — Booth L056 was among the most product-rich exhibitors in Pavilion 3, presenting a suite of containment and sterility assurance solutions that together address the contamination control requirements of sterile pharmaceutical manufacturing. The Sterility Test Isolator ensures that sterility testing occurs in a validated, contaminant-free environment — critical for avoiding false-positive and false-negative results that can either delay batch release or mask genuine contamination events. The Glow Leak Tester simultaneously tests the integrity of multiple gloves in isolators and RABS systems, detecting leaks as small as 50–100 microns and generating GMP-compliant PDF reports automatically. The Astracec CCIT system for IV bags uses Probe Position Decay technology for non-destructive leak detection down to 1 micron — protecting IV bag integrity where even microscopic defects pose direct patient safety risks. The ZHEROX® product family — comprising the portable B-pack, the room-scale ZHEROX Light (for environments up to 300 m³), and the ZHEROX Fixed System (for permanent cleanroom installation) — provides a scalable portfolio of electroactivated hydrogen peroxide biodecontamination solutions that together address every cleanroom and controlled environment scenario from spot decontamination to fully automated integrated building-management-system-connected sterilisation. The combined Svan portfolio at this show was arguably the most coherent single-exhibitor containment and sterility assurance offering on the entire expo floor.
iGene Labserve Pvt. Ltd. — Booth N021 demonstrated two products whose value lies in the intersection of engineering thoughtfulness and daily laboratory use. The Single Lever Autoclave — with its hydraulic lid control, single-lever opening mechanism, and leak-proof silicone gasket — addresses the ergonomic and safety failures of conventional autoclave designs that rely on multi-step clamping and offer no lid position control. The Low Footprint Triple Deck Incubator Shaker integrates temperature, humidity, CO₂, O₂, RPM, and illumination control in a compact triple-deck format, maximising flask capacity within a minimal bench footprint — a direct response to the space constraints of Indian biotech startups and CRO laboratories operating in premium-cost urban facilities.
Sashwat Lab Solutions — Booth L051 presented the Cleansol Laboratory Glassware Washer — a validated glassware cleaning platform that replaces manual washing with automated, reproducible cleaning cycles. In regulated pharmaceutical laboratories, validated glassware cleaning is a GMP requirement, not merely a convenience, and the documented cleaning performance of automated platforms directly reduces the risk of cross-contamination between analytical runs.
Mehrotra Biotech Pvt. Ltd. — Booth DO31 occupied one of Pavilion 1’s largest single-company footprints, presenting an integrated laboratory infrastructure portfolio covering Biosafety Cabinet Class II Type A2, Orbital Shaker, Centrifuge, Hot Air Oven, –86°C Deep Freezer, –20°C Deep Freezer, Laboratory Refrigerator, and Water Bath — in effect, the core cold-chain, thermal processing, and biological safety infrastructure required to equip a complete microbiology or cell biology laboratory. Mehrotra’s proposition is one of portfolio breadth under a single quality umbrella, reducing the multi-vendor complexity that plagues laboratory procurement in India.
M/s Metacryo Pvt. Ltd. — Booth L034 presented India’s first fully indigenous AI-powered cryogenic sample storage system — the MetaCryo Automated Liquid Nitrogen Storage Tank. Operating in the vapor phase at below –139°C, with a rotating turntable, automated level and temperature control, remote monitoring, and remote alarm systems, and claiming the lowest nitrogen evaporation rate (NER) globally, this is a significant Made in India achievement in a product category previously dominated entirely by imports. For biobanks, biosimilar manufacturers, and clinical research organisations, the ability to source world-class cryogenic infrastructure from a domestic manufacturer with comprehensive service and support networks represents both a cost advantage and a supply chain resilience gain.
Biolinx Labsystems Private Limited — Booth K061 presented the Bio-Shot Labs E. Coli Positive Control — a pharmaceutical microbiology quality control tool that provides quantified live cultures as positive controls for bioburden testing, USP <51>, <61>, <62> compliance, ISO 17034 certified reference materials, and EP 2.6.12/2.6.13 pharmacopoeial methods. It is precisely the kind of product whose importance is invisible until it is absent: without reliable positive controls, microbiological assay validation is compromised, and the regulatory consequences of that compromise can be severe.
Erweka India Pvt. Ltd. — Booth K062 presented the RoboDis II+ fully automated dissolution testing system — the only fully automatic dissolution system on the market capable of testing up to 10 batches according to USP methods 1 (basket) or 2 (paddle), fully compliant with USP, EP, and JP pharmacopoeias, and capable of running 40 batches in non-stop 24/7 operation with computer-controlled processes that eliminate human intervention. For pharmaceutical quality control laboratories running dissolution testing as a primary release method across large batch volumes, the productivity multiplier and human-error elimination of full automation at this scale are transformative.
WHAT THE PRODUCT MIX REVEALS
Walking the full floor of analytica Lab India and PharmaCore India 2026 over three days, a number of patterns emerge that are more than the sum of individual product demonstrations.
The first is the sheer range of India’s pharmaceutical manufacturing capability. From the softgel specialists of Baroda and the suppository manufacturers of Pune to the global biosimilar developers of Mumbai and the corticosteroid API chemists of Ahmedabad, the exhibitor profile at PharmaCore India 2026 defies any simple characterisation of Indian pharma as a generic formulation industry. It is, in practice, a deeply diversified manufacturing ecosystem whose full capability is rarely visible in any single forum.
The second is the acceleration of digitisation and data integrity investment. ValGenesis, OASIS I-TECH, Lab Iconics, and Soham ERP are not peripheral exhibitors at a trade fair that is primarily about tangible products. They represent a structural shift in how Indian pharmaceutical manufacturers are approaching regulatory compliance — moving from paper-based, reactive systems toward digitally integrated, proactive compliance architectures. The Schedule M revision and the continued focus of CDSCO and FDA inspections on data integrity have made this investment not merely desirable but commercially existential.
The third is the seriousness with which Indian manufacturers are engaging the export diversification imperative. The presence of MSB Chemical with its US-DMF grade ethanol, Misom Labs with its Malta-based EU/UK market access platform, SG Healthcare with its ARV and immunosuppressant export manufacturing, and S Kant Healthcare with its multi-regulatory approval portfolio — all of these represent a pharmaceutical sector that is not merely reacting to US market volatility but actively building the regulatory and operational infrastructure for a more geographically distributed export base.
The fourth, and perhaps most important, is the invisible presence that pervades the entire exhibition: the patient. Every product on display — from the AminoSAAYA amino acid analyser to the RoboDis II+ dissolution tester to the ZHEROX biodecontamination system to the Halewood ORS sachets — exists in service of a single chain of consequence that ends with a human being receiving a medicine that is safe, effective, and correctly manufactured. The exhibitors at this fair know this, even when they are presenting instruments rather than drug products. The best booths — the ones that held visitors longest — were those where the connection between the product on the stand and the patient at the end of the supply chain was made explicit, concrete, and felt.
analytica Lab India and PharmaCore India 2026 is, in that sense, a fair that takes its purpose seriously. The industry it serves cannot afford otherwise.
